Literature DB >> 18442953

The prevalence of cystic fibrosis in the European Union.

Philip M Farrell1.   

Abstract

This study combined a variety of methods to determine the prevalence of cystic fibrosis in the European Union. The results of literature reviews, surveys, and registry analyses revealed a mean prevalence of 0.737/10,000 in the 27 EU countries, which is similar to the value of 0.797 in the United States, and only one outlier, namely the Republic of Ireland at 2.98.

Entities:  

Mesh：

Year:  2008        PMID： 18442953     DOI： 10.1016/j.jcf.2008.03.007

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.482


  112 in total

1.  Notable contribution of large CFTR gene rearrangements to the diagnosis of cystic fibrosis in fetuses with bowel anomalies.

Authors:  Alix de Becdelièvre; Catherine Costa; Annick LeFloch; Marie Legendre; Jean-Marie Jouannic; Jacqueline Vigneron; Jean-Luc Bresson; Stéphanie Gobin; Josiane Martin; Michel Goossens; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2010-05-26       Impact factor: 4.246

2.  Expanded newborn screening in Greece: 30 months of experience.

Authors:  Yannis L Loukas; Georgios-Stefanos Soumelas; Yannis Dotsikas; Vassiliki Georgiou; Elina Molou; Georgia Thodi; Maria Boutsini; Sofia Biti; Konstantinos Papadopoulos
Journal:  J Inherit Metab Dis       Date:  2010-08-19       Impact factor: 4.982

3.  Newborn screening for cystic fibrosis: Polish 4 years' experience with CFTR sequencing strategy.

Authors:  Agnieszka Sobczyńska-Tomaszewska; Mariusz Ołtarzewski; Kamila Czerska; Katarzyna Wertheim-Tysarowska; Dorota Sands; Jarosław Walkowiak; Jerzy Bal; Tadeusz Mazurczak
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

4.  Parents' experience with positive newborn screening results for cystic fibrosis.

Authors:  Inken Brockow; Uta Nennstiel
Journal:  Eur J Pediatr       Date:  2019-03-09       Impact factor: 3.183

5.  A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.

Authors:  Manon F Pritchard; Lydia C Powell; Alison A Jack; Kate Powell; Konrad Beck; Hannah Florance; Julian Forton; Philip D Rye; Arne Dessen; Katja E Hill; David W Thomas
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

6.  The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.

Authors:  Simon Frey; Tom Stargardt; Udo Schneider; Jonas Schreyögg
Journal:  Pharmacoeconomics       Date:  2019-08       Impact factor: 4.981

7.  High rate of Exophiala dermatitidis recovery in the airways of patients with cystic fibrosis is associated with pancreatic insufficiency.

Authors:  Nahid Kondori; Marita Gilljam; Anders Lindblad; Bodil Jönsson; Edward R B Moore; Christine Wennerås
Journal:  J Clin Microbiol       Date:  2011-01-05       Impact factor: 5.948

8.  Genomic Analysis of Mycobacterium abscessus Complex Isolates Collected in Ireland between 2006 and 2017.

Authors:  Natalia Redondo; Simone Mok; Lorraine Montgomery; Peter R Flanagan; Eleanor McNamara; Edmond G Smyth; Niamh O'Sullivan; Kirsten Schaffer; Thomas R Rogers; Margaret M Fitzgibbon
Journal:  J Clin Microbiol       Date:  2020-06-24       Impact factor: 5.948

9.  Fetal Gene Therapy Using a Single Injection of Recombinant AAV9 Rescued SMA Phenotype in Mice.

Authors:  Afrooz Rashnonejad; Gholamhossein Amini Chermahini; Cumhur Gündüz; Hüseyin Onay; Ayça Aykut; Burak Durmaz; Meral Baka; Qin Su; Guangping Gao; Ferda Özkınay
Journal:  Mol Ther       Date:  2019-08-31       Impact factor: 11.454

Review 10.  Interventions for preventing and managing advanced liver disease in cystic fibrosis.

Authors:  Senthil K Palaniappan; Nan Nitra Than; Aung Win Thein; Soe Moe; Indra van Mourik
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.